Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector
GAITHERSBURG, Md. , Oct. 04, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the...
Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
Transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017 GAITHERSBURG, Md. , Oct. 03, 2017 (GLOBE NEWSWIRE) — Emergent...
Emergent BioSolutions Announces Closing of New $200 Million Senior Secured Credit Facility
Facility Includes an Accordion Feature Enabling $100 Million of Additional Capacity for a Total of $300 Million GAITHERSBURG, Md. , Oct. 02, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc....
Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On Contract Valued at Up to $171 Million
GAITHERSBURG, Md. , Sept. 25, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a five-year follow-on contract valued at up to approximately...
Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure
GAITHERSBURG, Md. , Sept. 18, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at approximately $63 million by the...